NewTimeSpace News: As of 13:35 on March 20, 2026, the CSI TCM Index (930641) edged up 0.90%. Its constituent stocks posted mixed gains, with Dong'e Ejiao rising 7.16%, China Resources Jiangzhong Pharmaceutical up 6.76%, Lingrui Pharmaceutical climbing 2.99%, Jichuan Pharmaceutical advancing 2.85% and China Resources Sanjiu Medical & Pharmaceutical increasing 2.13%.Penghua CSI Chinese Medicine ETF(159647) rose 0.84% to a latest price of RMB 0.96. (The stocks listed above are only constituent stocks of the index and do not constitute any specific investment recommendation.)

In terms of liquidity,Penghua CSI Chinese Medicine ETFrecorded an intraday turnover rate of 1.07% with a trading volume of RMB 15.9 million. Over a longer horizon, as of March 19, the ETF had an average daily trading volume of RMB 32.6266 million in the past year.

In terms of scale,Penghua CSI Chinese Medicine ETFsaw a remarkable growth with a scale increase of RMB 677 million in the past year, ranking the top 25% among comparable funds in terms of newly added scale. (Data source: Wind)

In terms of shares,Penghua CSI Chinese Medicine ETFachieved a significant rise with a share increase of 114 million in the past three months, ranking the top 25% among comparable funds in terms of newly added shares. (Data source: Wind)

Data showed that leveraged funds have been continuously building positions in the ETF. The latest margin purchase amount ofPenghua CSI Chinese Medicine ETFreached RMB 1.3742 million, with the latest margin balance standing at RMB 28.0813 million. (Data source: Wind)

In terms of earnings capacity, as of March 19, 2026, since its establishment,Penghua CSI Chinese Medicine ETFhas achieved a maximum monthly return of 16.26%, a longest consecutive rising streak of 5 months with a cumulative increase of 20.28% during the period, and an average yield of 4.98% in rising months. As of March 19, 2026, the ETF has an annualized return of 2.72% outperforming the benchmark in the past two years, ranking the top 25% among comparable funds.

In terms of drawdown, as of March 19, 2026, the maximum drawdown ofPenghua CSI Chinese Medicine ETFwas 5.49% year-to-date, with a drawdown of 0.05% relative to the benchmark, the smallest among comparable funds.

On the fee front,Penghua CSI Chinese Medicine ETFhas a management fee rate of 0.50% and a custodian fee rate of 0.10%, the lowest among comparable funds.

In terms of tracking accuracy, as of March 19, 2026, the tracking error ofPenghua CSI Chinese Medicine ETFwas 0.031% in the past six months, the highest in tracking accuracy among comparable funds.

From a valuation perspective, the latest trailing twelve months price-to-earnings ratio (PE-TTM) of the CSI TCM Index tracked byPenghua CSI Chinese Medicine ETFstands at only 23.53 times, at the 5.02% quantile over the past year. This means the valuation is lower than that in more than 94.98% of the time in the past year, hovering at a historically low level.

Penghua CSI Chinese Medicine ETFclosely tracks the CSI TCM Index, which selects listed company securities engaged in businesses such as TCM production and sales as index samples to reflect the overall performance of listed companies related to the TCM concept.

Data showed that as of February 27, 2026, the top 10 weight stocks of the CSI TCM Index (930641) were Yunnan Baiyao, Pientzehuang, Dong'e Ejiao, Tongrentang, China Resources Sanjiu Medical & Pharmaceutical, Jilin Aodong Pharmaceutical, Baiyunshan Pharmaceutical, Yiling Pharmaceutical, Zhongsheng Pharmaceutical and Darentang Pharmaceutical, accounting for a total of 55.23% of the index's weight. (The stocks listed above are only constituent stocks of the index and do not constitute any specific investment recommendation.)

CGS stated that the 15th Five-Year Plan proposes to improve the coordinated development and governance mechanism of medical care, medical insurance and pharmaceuticals. The biopharmaceutical industry has been listed as a national "emerging pillar industry" for the first time, marking a further upgrade of its strategic positioning.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.